Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by BayStreetWildon Dec 10, 2021 10:12am
114 Views
Post# 34218282

RE:No More Equity Issues

RE:No More Equity Issues

time to sell dialco. If they got enough for it to finish our main trial I would be happy. 


Accountprince wrote: I agree with Revten and MM about the buying opportunity.  So I have no problem with existing shareholders acquiring at low prices to combat the regular dilution that has occurred through bad equity raises.

Where I do have a problem is the apparent careless and thoughtless issue of equity spearheaded by our CFO/COO/CEO.  We've witnessed an issue at $0.60 per unit in 2020 that served to drag the trading price from around $0.80 per share into the $0.55 range.  Poor planning or poor execution or both.  Then this year an apparent spur of the moment issue at $0.425 per unit when we were trading in the mid to upper $0.55 per share range.  Continuing poor planning or poor execution or both.

My biggest fear is the bumbling will continue while we're in the $0.21 per share range.  Will an idiotic issue be done at say $0.15 per unit?  We should insist that a proper marketing be done now with assurances no more share issues will be done until it bears fruit.  Indeed we could even set a floor price of returning to the $0.80 per share level we had before the bumbling started.  Then issues can be done at that level or better.  If we need real IR and promotion in Canada and the US then get some.  We have been spending valuable dollars (raised at stupidly low share prices) to pay these people overseeing the program.  Time for us to get real value for dollars spent including the C suite.

 

<< Previous
Bullboard Posts
Next >>